Joshua E. Reuss

2.2k total citations
54 papers, 521 citations indexed

About

Joshua E. Reuss is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joshua E. Reuss has authored 54 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Joshua E. Reuss's work include Lung Cancer Treatments and Mutations (35 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Colorectal Cancer Treatments and Studies (12 papers). Joshua E. Reuss is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Colorectal Cancer Treatments and Studies (12 papers). Joshua E. Reuss collaborates with scholars based in United States, Canada and Spain. Joshua E. Reuss's co-authors include Patrick M. Forde, Jarushka Naidoo, Samuel Rosner, Stephen V. Liu, Alejandro A. Gru, Elizabeth Gaughan, Craig L. Slingluff, Paul R. Kunk, Karthik Suresh and Julie R. Brahmer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Joshua E. Reuss

47 papers receiving 514 citations

Peers

Countries citing papers authored by Joshua E. Reuss

Since Specialization

Citations

This map shows the geographic impact of Joshua E. Reuss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua E. Reuss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua E. Reuss more than expected).

Fields of papers citing papers by Joshua E. Reuss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua E. Reuss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua E. Reuss. The network helps show where Joshua E. Reuss may publish in the future.

Co-authorship network of co-authors of Joshua E. Reuss

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua E. Reuss. A scholar is included among the top collaborators of Joshua E. Reuss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua E. Reuss. Joshua E. Reuss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inpatient Immunotherapy Outcomes Study: A Multicenter Retrospective Analysis 2025 ·JCO Oncology Practice ·Fauzia Riaz, John L. Vaughn, (unknown), (unknown), Hoda E. Sayegh, (unknown), (unknown), Melanie Wain Kier, (unknown), (unknown), Osama Abdelghany, Roger B. Cohen, Ravi B. Parikh, Joshua E. Reuss, Elizabeth Pršić, Deborah B. Doroshow	3
2	Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis 2025 ·Clinical Lung Cancer ·(unknown), Gabriel Lenz, (unknown), Mariah Malak Bilalaga, (unknown), Nelly Müller, (unknown), (unknown), Marcelo Corassa, Andrés F. Cardona, Joshua E. Reuss, Bruna Pellini	0
3	Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1 2025 ·Journal of Clinical Oncology ·Joshua E. Reuss, Sara Kuruvilla, Nofisat Ismaila, Ibrahim Azar, Jill Feldman, Naoki Furuya, Paul Wheatley‐Price, (unknown), Ana I. Velázquez, Yubao Wang, Natasha B. Leighl	1
4	Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 2025 ·Journal of Clinical Oncology ·Dwight H. Owen, Nofisat Ismaila, (unknown), Jill Feldman, Shirish M. Gadgeel, Michael P. Mullane, Jarushka Naidoo, Carolyn J. Presley, Joshua E. Reuss, Navneet Singh, Jyoti D. Patel	4
5	1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159 2024 ·Annals of Oncology ·Joshua E. Reuss, Cheuk Hong Leung, (unknown), Nicolas Zhou, (unknown), Apar Pataer, William N. William, Joseph H. Taube, Stephen Broderick, (unknown), David R. Jones, Don L. Gibbons, John V. Heymach, Valsamo Anagnostou, Heather Lin, J.J. Lee, Boris Sepesi, Jamie E. Chaft, (unknown), Tina Cascone	0
6	1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), Luis Paz‐Ares, (unknown), (unknown), Aurélie Swalduz, Anna Minchom, Joshua E. Reuss, (unknown), (unknown), (unknown), Benjamin Solomon, (unknown), (unknown), Yinghui Sun, Jing Shen, (unknown), (unknown)	9
7	Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer 2024 ·Clinical Lung Cancer ·Michael Marrone, Joshua E. Reuss, (unknown), Brian Neelon, Jun O. Liu, Julie R. Brahmer, Elizabeth A. Platz	4
8	Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer 2023 ·Clinical Cancer Research ·Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, (unknown), Janis M. Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde	44
9	P2.31-05 Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data 2023 ·Journal of Thoracic Oncology ·(unknown), Lova Sun, Joshua E. Reuss, (unknown), Geoffrey Liu, (unknown), Stephen V. Liu, (unknown), Tejas Patil, Jorge J. Nieva, (unknown), Kristen A. Marrone, Vincent K. Lam, William Schwartzman, (unknown), Keith L. Miller, D. Ross Camidge, Charu Aggarwal, Wei‐Ting Hwang, Melina E. Marmarelis	0
10	Spectrum of acquired KRAS mutations in driver mutation-positive non-small cell lung cancer. 2023 ·Journal of Clinical Oncology ·Joshua E. Reuss, Nishant Gandhi, Phillip Walker, Jorge J. Nieva, (unknown), Jennifer W. Carlisle, Aakash Desai, Ari M. Vanderwalde, C. Patrick, Stephen V. Liu	0
11	1470P Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis 2023 ·Annals of Oncology ·Joshua E. Reuss, Michael Marrone, Albert Crawford, Brian Neelon, Junliang Liu, Elizabeth A. Platz, Julie R. Brahmer	2
12	Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors 2023 ·Clinical Lung Cancer ·(unknown), Aanika Balaji, Joseph C. Murray, Joshua E. Reuss, (unknown), Kathleen Bennett, Jarushka Naidoo	3
13	ERBB family fusions are recurrent and actionable oncogenic targets across cancer types 2023 ·Frontiers in Oncology ·Laura Schubert, Andrew Elliott, Anh T. Le, Adriana Estrada‐Bernal, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Joshua E. Reuss, Sai‐Hong Ignatius Ou, (unknown), Christian A. Thomas, Sourat Darabi, W. Michael Korn, Wafik S. El‐Deiry, Stephen V. Liu	8
14	Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report 2022 ·Translational Lung Cancer Research ·Vincent Yeung, Chul Kim, Lesli A. Kiedrowski, Stephen V. Liu, Joshua E. Reuss	4
15	Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report 2022 ·JTO Clinical and Research Reports ·(unknown), Jennifer A. Marks, (unknown), Emily A. Sloan, (unknown), (unknown), Joshua E. Reuss, (unknown), Stephen V. Liu, Chul Kim	9
16	Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class 2022 ·Current Oncology Reports ·Jennifer A. Marks, (unknown), Stephen V. Liu, Joshua E. Reuss	9
17	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments 2021 ·Clinical Lung Cancer ·Joshua E. Reuss, (unknown), Stephen V. Liu	13
18	Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors 2020 ·Clinical Cancer Research ·Osama E. Rahma, Joshua E. Reuss, Anita Giobbie‐Hurder, (unknown), (unknown), (unknown), Seema Gupta, Richard Simon, Samir N. Khleif	3
19	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond 2020 ·Current Oncology Reports ·Joshua E. Reuss, Karthik Suresh, Jarushka Naidoo	27
20	A review of canakinumab and its therapeutic potential for non-small cell lung cancer 2019 ·Anti-Cancer Drugs ·Kara M. Schenk, Joshua E. Reuss, Karin Choquette, Alexander I. Spira	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact